HCA Healthcare (HCA) Q3 2026 Earnings Call: Q&A Summary

Q: A.J. Rice with UBS asked about the magnitude of exchange headwinds for 2027 and if cost savings would match the $400 million resiliency program.

A: Mike Marks and Sam Hazen noted that planning is in early stages and depends on Q4 results and enrollment data. They stated that resiliency is a strategic, ongoing program that will continue to generate value beyond 2027.

Q: Pito Chickering with Deutsche Bank asked to confirm if 2027 core EBITDA growth is in the 4% to 6% range and how resiliency drives that.

A: Mike Marks explained that resiliency is part of core operations. He noted that the company saw 10% core growth in the third quarter and that the upper half of 2026 guidance implies confidence in the fourth quarter.

Q: Ann Hynes with Mizuno asked if the flat 2027 guidance assumes any benefit from the proposed 340B Medicare Opts rule.

A: Mike Marks stated that the company views the proposed rule as a positive factor for 2027 but is not publicly sizing the benefit at this time.

Q: Ben Hendrix with RBC Capital Markets asked about the surgical backdrop and if pent-up demand could provide upside to the 2% to 3% volume growth forecast.

A: Sam Hazen stated they have not finalized surgical components for 2027. While elective surgery faces macro headwinds like coverage and affordability, other services like cardiac and neonatal are strong, providing diversification.

Q: Ryan Langston with TD Cowen asked for an update on ASC versus HOPD surgical volumes in the third quarter.

A: Mike Marks reported that ASC surgery volumes were down 5.4% and hospital-based outpatient surgeries were down 2.9%, with the primary pressure being exchange-related.

Q: Sarah James with Cantor Fitzgerald asked how much surgical pressure is exchange-related versus affordability and if they assume a tailwind in Q4.

A: Sam Hazen stated that the exchange environment is a significant piece of the elective equation. They are not assuming any tailwind in Q4 beyond normal seasonality.

Q: Brian Tanquilut with Jefferies asked about SWB and other OpEx trends, specifically regarding temp staffing and resiliency.

A: Mike Marks noted that SWB was up sequentially due to merit adjustments, but cost per equivalent admission was flat to prior year and down 40 basis points sequentially. Professional fees were up 12% versus prior year.

Q: Craig Hettenbach with Morgan Stanley asked about resiliency applications and untapped opportunities.

A: Mike Marks stated that resiliency focuses on revenue integrity, asset optimization, variable costs, and fixed costs. Digital transformation and shared service expansion are key enablers for future years.

Q: Matthew Gillmor with KeyBanc asked about drivers of the acceleration in insured revenue per equivalent admission.

A: Mike Marks attributed the acceleration to strong commercial volume growth of 2.7%, solid rate growth, and improved collection capabilities from Parallon.

Q: Sean Dodge with BMO Capital Markets asked about visibility for Q4 and if volume growth will continue to improve.

A: Mike Marks stated that the upper half of guidance implies core growth remains consistent in Q4. They expect normal seasonal trends and continued resiliency performance.

Q: Kevin Fischbeck with Bank of America asked to clarify the guidance increase regarding supplemental payments and payer mix headwinds.

A: Mike Marks explained the increase reflects $300 million more in supplemental payments, offset by $100 million to $200 million in increased exchange headwinds, plus strong core growth.

Q: Whit Mayo with Leerink asked if the HICS headwind worsened in specific markets and about AR collectability.

A: Mike Marks reported that HICS results were slightly higher than estimated, with a 19% decline versus the expected 15% to 16%, representing about 2,000 adjusted admissions.

Q: Justin Lake with Wolfe Research asked for a breakdown of the $550 million to $650 million Medicaid supplemental payment headwind for 2027.

A: Mike Marks explained the headwind is primarily due to grandfathered approvals in 2026 related to prior years, specifically in Virginia and Georgia.

Q: Scott Fidel with Goldman Sachs asked about H.R.1 and potential impacts from work requirements on Medicaid.

A: Mike Marks stated that work requirements for able-bodied adults in expansion states could impact 15% to 20% of Medicaid volume, though they are not ready to size the earnings impact for 2027.

Q: Stephen Baxter with Wells Fargo asked for Medicare and Medicaid adjusted admission growth rates.

A: Mike Marks reported that Medicare adjusted admissions were up 3.2% year-over-year, which represented an 8% sequential improvement from the second quarter.

Q: Jason Cassorla with Guggenheim Securities asked to quantify the drivers of volume strength and how they fit into the 2% to 3% growth target.

A: Sam Hazen attributed growth to population trends, market share gains, and an ambulatory platform of nearly 3,000 units. They are also focused on patient flow and physician engagement.

Q: Raj Kumar with Stephens asked if payers are embedding coding accuracy assumptions in 2028 contracts.

A: Sam Hazen stated that contracting is transparent and they are making progress on 2028 cycles. They are working with payers to reduce administrative friction.

Q: Benjamin Rossi with JPMorgan asked if they are considering market exits or acquisitions.

A: Sam Hazen stated they have already optimized the portfolio and do not see significant changes to market configuration. They remain opportunistic regarding new markets if they fit the model.

Q: Andrew Mok with Barclays asked about the impact of the inpatient-only list removal.

A: Mike Marks and Sam Hazen noted that the first year of the three-year phase-out focuses on ortho and musculoskeletal procedures. They are investing in both inpatient and outpatient platforms to adapt.